Ignite Creation Date:
2025-12-24 @ 3:37 PM
Ignite Modification Date:
2025-12-28 @ 2:19 PM
Study NCT ID:
NCT00517192
Status:
TERMINATED
Last Update Posted:
2014-05-14
First Post:
2007-08-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Argentina', 'Brazil', 'Mexico', 'Poland', 'Switzerland']}, 'conditionBrowseModule': {'meshes': [{'id': 'D015658', 'term': 'HIV Infections'}], 'ancestors': [{'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D015229', 'term': 'Sexually Transmitted Diseases, Viral'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}, {'id': 'D016180', 'term': 'Lentivirus Infections'}, {'id': 'D012192', 'term': 'Retroviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007153', 'term': 'Immunologic Deficiency Syndromes'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C107201', 'term': 'tipranavir'}, {'id': 'D000069454', 'term': 'Darunavir'}, {'id': 'D019438', 'term': 'Ritonavir'}], 'ancestors': [{'id': 'D013449', 'term': 'Sulfonamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D002219', 'term': 'Carbamates'}, {'id': 'D000144', 'term': 'Acids, Acyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D013450', 'term': 'Sulfones'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D005663', 'term': 'Furans'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D013844', 'term': 'Thiazoles'}, {'id': 'D001393', 'term': 'Azoles'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clintriage.rdg@boehringer-ingelheim.com', 'phone': '1-800-243-0127', 'title': 'Boehringer Ingelheim Pharmaceuticals', 'organization': 'Boehringer Ingelheim Pharmaceuticals'}, 'certainAgreement': {'otherDetails': 'Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From the signing of the informed consent onwards through the observational phase (50 weeks).', 'eventGroups': [{'id': 'EG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral', 'otherNumAtRisk': 19, 'otherNumAffected': 12, 'seriousNumAtRisk': 19, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral', 'otherNumAtRisk': 20, 'otherNumAffected': 7, 'seriousNumAtRisk': 20, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Angina pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Odynophagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Cytolytic hepatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Subcutaneous abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Tracheitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Blood creatine phosphokinase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Productive cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Facial wasting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}], 'seriousEvents': [{'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Gangrene', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Spondylolisthesis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Peroneal nerve palsy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Radiculopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Iliac artery thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}, {'term': 'Peripheral ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 12.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Time to Virologic Failure Through 48 Weeks of Treatment, Using Viral Load (VL) < 50 Copies/Millilitre (mL) as the Response Criterion.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': '48 weeks of treatment', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Treatment Response at Week 48, Using VL < 50 Copies/mL as the Response Criterion and the FDA Definition for Handling Drug Discontinuations ((NCF) Non-Completers=Failure).', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': '48 weeks of treatment', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Intent-To-Treat Analysis of Virologic Response at Week 48, Using VL < 50 Copies/mL as the Response Criterion Where Patients Are Followed Until Week 48 for VL Regardless of Whether or Not They Remain on Study Drug.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': '48 weeks of treatment', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Time to Virologic Failure Through 48 Weeks of Treatment, Using VL < 400 Copies/mL as the Response Criterion.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': '48 weeks of treatment', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Response up to 48 Weeks Using VL < 50 Copies/mL Using Censored', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to 48 weeks', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Response up to 48 Weeks Using VL < 50 Copies/mL Using NCF', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to 48 weeks', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Response up to 48 Weeks Using VL < 50 Copies/mL Using Intent-to-treat', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to 48 weeks', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Response up to 48 Weeks Using VL < 400 Copies/mL Using Censored', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to 48 weeks', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Response up to 48 Weeks Using VL < 400 Copies/mL Using NCF', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to 48 weeks', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Response up to 48 Weeks Using VL < 400 Copies/mL Using Intent-to-treat', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to 48 weeks', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Censored', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to 48 weeks', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using NCF', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to 48 weeks', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Intent-to-treat', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to 48 weeks', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Daily Average in CD4+ Cell Count Change From Baseline at up to Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to week 8', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Daily Average in CD4+ Cell Count Change From Baseline up to Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to week 24', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Daily Average in CD4+ Cell Count Change From Baseline up to Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to week 48', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Daily Average in Viral Load Change From Baseline up to Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to week 8', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Daily Average in Viral Load Change From Baseline up to Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to week 24', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Daily Average in Viral Load Change From Baseline up to Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to week 48', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in CD4+ Cell Count up to Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to week 48', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in log10 Viral Load up to Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'up to week 48', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Occurrence of New AIDS Progression Events or Death', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'OG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'timeFrame': 'through 48 weeks of treatment', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'FG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '19'}, {'groupId': 'FG001', 'numSubjects': '20'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '19'}, {'groupId': 'FG001', 'numSubjects': '20'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Early termination of the trial', 'reasons': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '18'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'BG000'}, {'value': '20', 'groupId': 'BG001'}, {'value': '39', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Tipranavir 500 mg/Ritonavir 200 mg', 'description': 'Tipranavir (TPV) 250 mg soft gelatin capsules Ritonavir (RTV) 100 mg soft gelatin capsules dose: 500 mg TPV/200 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'BG001', 'title': 'Darunavir 600 mg/Ritonavir 100 mg', 'description': 'Prezista® (DRV) 300 mg tablets Ritonavir (RTV) 100 mg soft gelatin capsules dose: 600 mg DRV/100 mg RTV, twice daily mode of admin.: Oral'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '44.3', 'spread': '6.1', 'groupId': 'BG000'}, {'value': '43.1', 'spread': '6.2', 'groupId': 'BG001'}, {'value': '43.6', 'spread': '6.1', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '32', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 40}}, 'statusModule': {'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2007-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-04', 'lastUpdateSubmitDate': '2014-04-25', 'studyFirstSubmitDate': '2007-08-15', 'resultsFirstSubmitDate': '2009-09-18', 'studyFirstSubmitQcDate': '2007-08-15', 'lastUpdatePostDateStruct': {'date': '2014-05-14', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2009-09-18', 'studyFirstPostDateStruct': {'date': '2007-08-16', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2009-10-23', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time to Virologic Failure Through 48 Weeks of Treatment, Using Viral Load (VL) < 50 Copies/Millilitre (mL) as the Response Criterion.', 'timeFrame': '48 weeks of treatment'}], 'secondaryOutcomes': [{'measure': 'Treatment Response at Week 48, Using VL < 50 Copies/mL as the Response Criterion and the FDA Definition for Handling Drug Discontinuations ((NCF) Non-Completers=Failure).', 'timeFrame': '48 weeks of treatment'}, {'measure': 'Intent-To-Treat Analysis of Virologic Response at Week 48, Using VL < 50 Copies/mL as the Response Criterion Where Patients Are Followed Until Week 48 for VL Regardless of Whether or Not They Remain on Study Drug.', 'timeFrame': '48 weeks of treatment'}, {'measure': 'Time to Virologic Failure Through 48 Weeks of Treatment, Using VL < 400 Copies/mL as the Response Criterion.', 'timeFrame': '48 weeks of treatment'}, {'measure': 'Response up to 48 Weeks Using VL < 50 Copies/mL Using Censored', 'timeFrame': 'up to 48 weeks'}, {'measure': 'Response up to 48 Weeks Using VL < 50 Copies/mL Using NCF', 'timeFrame': 'up to 48 weeks'}, {'measure': 'Response up to 48 Weeks Using VL < 50 Copies/mL Using Intent-to-treat', 'timeFrame': 'up to 48 weeks'}, {'measure': 'Response up to 48 Weeks Using VL < 400 Copies/mL Using Censored', 'timeFrame': 'up to 48 weeks'}, {'measure': 'Response up to 48 Weeks Using VL < 400 Copies/mL Using NCF', 'timeFrame': 'up to 48 weeks'}, {'measure': 'Response up to 48 Weeks Using VL < 400 Copies/mL Using Intent-to-treat', 'timeFrame': 'up to 48 weeks'}, {'measure': 'Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Censored', 'timeFrame': 'up to 48 weeks'}, {'measure': 'Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using NCF', 'timeFrame': 'up to 48 weeks'}, {'measure': 'Response up to 48 Weeks Using at Least a 1 log10 Reduction in Viral Load From Baseline Using Intent-to-treat', 'timeFrame': 'up to 48 weeks'}, {'measure': 'Daily Average in CD4+ Cell Count Change From Baseline at up to Week 8', 'timeFrame': 'up to week 8'}, {'measure': 'Daily Average in CD4+ Cell Count Change From Baseline up to Week 24', 'timeFrame': 'up to week 24'}, {'measure': 'Daily Average in CD4+ Cell Count Change From Baseline up to Week 48', 'timeFrame': 'up to week 48'}, {'measure': 'Daily Average in Viral Load Change From Baseline up to Week 8', 'timeFrame': 'up to week 8'}, {'measure': 'Daily Average in Viral Load Change From Baseline up to Week 24', 'timeFrame': 'up to week 24'}, {'measure': 'Daily Average in Viral Load Change From Baseline up to Week 48', 'timeFrame': 'up to week 48'}, {'measure': 'Change From Baseline in CD4+ Cell Count up to Week 48', 'timeFrame': 'up to week 48'}, {'measure': 'Change From Baseline in log10 Viral Load up to Week 48', 'timeFrame': 'up to week 48'}, {'measure': 'Occurrence of New AIDS Progression Events or Death', 'timeFrame': 'through 48 weeks of treatment'}]}, 'conditionsModule': {'conditions': ['HIV Infections']}, 'referencesModule': {'references': [{'pmid': '22007990', 'type': 'DERIVED', 'citation': 'Elgadi MM, Piliero PJ. Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial. Drugs R D. 2011 Dec 1;11(4):295-302. doi: 10.2165/11596340-000000000-00000.'}]}, 'descriptionModule': {'briefSummary': 'The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir (TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600 mg /100 mg twice daily) in combination with investigator selected optimised background regimens in patients who are three-class (Nucleoside reverse transcriptase inhibitors (NRTI), Nonnucleoside reverse transcriptase inhibitors (NNRTI), and Protease inhibitor (PI)) treatment-experienced (a minimum of 3-months duration for each class) with resistance to more than one PI on the screening virtual phenotype resistance testing.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Signed informed consent prior to trial participation.\n2. HIV-1 infected male or female \\>18 years of age.\n3. Three-class (NRTI, NNRTI, and PI) treatment-experienced patients (a minimum of 3-months duration for each class or documented class hypersensitivity/intolerance) with resistance (minimal or reduced response) to more than one PI on the screening virtual phenotype resistance testing. In the case of NNRTIs, NNRTI resistance in the absence of exposure is equivalent to being NNRTI treatment experienced.\n4. Patient\'s optimized background regimen must contain one of the following ARV options:\n\n * A minimum of two genotypically active nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) reported as "maximal response" or "sensitive" on the screening virtual phenotype report.\n * A minimum of one genotypically active NRTI reported as "maximal response" or "sensitive" on the screening virtual phenotype report plus Enfuvirtide if not used previously.\n * A minimum of one genotypically active NRTI reported as "maximal response" or "sensitive" on the screening virtual phenotype report plus an integrase inhibitor if not used previously and if available through an expanded access program and allowed by local regulatory authorities.\n * A minimum of one genotypically active NRTI reported as "maximal response" or "sensitive" on the screening virtual phenotype report plus the CCR5 chemokine receptor antagonist Maraviroc if available through an expanded access program, not used previously and allowed by local regulatory authorities.\n * Zero or one genotypically active NRTI reported as "maximal response" or "sensitive" on the screening virtual phenotype report plus two of the following drugs, Enfuvirtide, an integrase inhibitor and Maraviroc if available, not used previously and allowed by local regulatory authorities.\n * Two genotypically partially active NRTIs (provided that they are not part of the current failing regimen) reported as "reduced response" on the screening virtual phenotype report plus one of the following drugs, Enfuvirtide, an integrase inhibitor or Maraviroc if available, not used previously and allowed by local regulatory authorities.\n5. Patient has been on their current (failing) PI-containing regimen for at least 8 weeks prior to randomization.\n6. Patient has on-going viral replication (defined as an HIV-1 viral load of ≥ 500 copies/mL) and a successful virtual phenotype obtained at screening.\n7. Any baseline CD4 cell count will be allowed.\n8. Karnofsky performance score of ≥ 70.\n9. Acceptable screening laboratory values that indicate adequate baseline organ function. Laboratory values are considered acceptable if the following apply:\n\n * ALT ≤2.5 x ULN and AST ≤2.5 x ULN (≤DAIDS Grade 1, Appendix 10.1).\n * Any DAIDS grade cholesterol, triglycerides, GGT, CPK or LDH is acceptable.\n * All other laboratory test values must be ≤DAIDS Grade 2.\n10. Willingness to initiate CD4+ cell count-guided chemoprophylaxis to prevent opportunistic infections.\n11. Willingness to abstain from ingesting substances which may alter plasma study drug levels by interaction with the cytochrome P450 system during the study.\n\nInclusion Criteria:\n\n1. Previous use of Tipranavir (TPV) or Darunavir (DRV).\n2. Full genotypic resistance (reported as minimal response) to Tipranavir (TPV) or Darunavir (DRV) on screening virtual phenotype:\n3. Female patient of child-bearing potential who:\n\n has a positive serum pregnancy test at screening, is breast feeding, is planning to become pregnant, is not willing to use double-barrier methods (simultaneous use of two different methods such as diaphragm with spermicidal substance and condom) of contraception or requires ethinyl estradiol administration. Barrier methods of contraception include diaphragm with spermicidal substance, condom for females, cervical caps and condoms.\n4. History of Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi\'s Sarcoma (KS), and/or any malignancy.\n5. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit.\n6. Use of immunomodulatory drugs (such as interferon, cyclosporin, hydroxyurea and interleukin 2) within 30 days prior to randomization.\n7. Current use of systemic cytotoxic chemotherapy.\n8. All contraindications listed in the product monographs of Aptivus, Prezista and Norvir.'}, 'identificationModule': {'nctId': 'NCT00517192', 'briefTitle': 'Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI', 'organization': {'class': 'INDUSTRY', 'fullName': 'Boehringer Ingelheim'}, 'officialTitle': 'A Prospective, Randomized, Open-labelled, Multi-centre Trial Comparing the Safety and Efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to That of Prezista® (Darunavir, DRV/r) in Three-class (NRTI, NNRTI, and PI) Treatment-experienced Patients With Resistance to More Than One PI. POTENT: PrOspecTive EvaluatioN of Tipranavir vs. Darunavir in Treatment Experienced Patients', 'orgStudyIdInfo': {'id': '1182.71'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Tipranavir', 'type': 'DRUG'}, {'name': 'Darunavir', 'type': 'DRUG'}, {'name': 'Ritonavir', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'city': 'Beverly Hills', 'state': 'California', 'country': 'United States', 'facility': '1182.71.1109 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 34.07362, 'lon': -118.40036}}, {'city': 'Fort Lauderdale', 'state': 'Florida', 'country': 'United States', 'facility': '1182.71.1101 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 26.12231, 'lon': -80.14338}}, {'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': '1182.71.1104 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': '1182.71.1115 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': '1182.71.1108 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': '1182.71.1126 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': '1182.71.1124 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': '1182.71.1116 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'city': 'Longview', 'state': 'Texas', 'country': 'United States', 'facility': '1182.71.1118 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 32.5007, 'lon': -94.74049}}, {'city': 'Brussels', 'country': 'Belgium', 'facility': '1182.71.3202 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Brussels', 'country': 'Belgium', 'facility': '1182.71.3203 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Brussels', 'country': 'Belgium', 'facility': '1182.71.3205 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Charleroi', 'country': 'Belgium', 'facility': '1182.71.3206 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.41136, 'lon': 4.44448}}, {'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': '1182.71.1002 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'city': 'Ottawa', 'state': 'Ontario', 'country': 'Canada', 'facility': '1182.71.1001 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': '1182.71.1003 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': '1182.71.1006 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': '1182.71.1010 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'city': 'Bondy', 'country': 'France', 'facility': '1182.71.3305A Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.9018, 'lon': 2.48931}}, {'city': 'Garches', 'country': 'France', 'facility': '1182.71.3303A Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.84226, 'lon': 2.18232}}, {'city': 'Lyon', 'country': 'France', 'facility': '1182.71.3301A Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'city': 'Lyon', 'country': 'France', 'facility': '1182.71.3312A Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'city': 'Paris', 'country': 'France', 'facility': '1182.71.3306A Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Paris', 'country': 'France', 'facility': '1182.71.3308A Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Tourcoing', 'country': 'France', 'facility': '1182.71.3310A Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.72391, 'lon': 3.16117}}, {'city': 'Berlin', 'country': 'Germany', 'facility': '1182.71.4902 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Frankfurt', 'country': 'Germany', 'facility': '1182.71.4907 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 49.68333, 'lon': 10.53333}}, {'city': 'Mainz', 'country': 'Germany', 'facility': '1182.71.4903 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'city': 'Athens', 'country': 'Greece', 'facility': '1182.71.3002 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'city': 'Athens', 'country': 'Greece', 'facility': '1182.71.3003 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'city': 'Piraeus', 'country': 'Greece', 'facility': '1182.71.3001 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 37.94203, 'lon': 23.64619}}, {'city': 'Antella (fi)', 'country': 'Italy', 'facility': '1182.71.3912 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 43.72774, 'lon': 11.32233}}, {'city': 'Brescia', 'country': 'Italy', 'facility': '1182.71.3901 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'city': 'Florence', 'country': 'Italy', 'facility': '1182.71.3908 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'city': 'Palermo', 'country': 'Italy', 'facility': '1182.71.3916 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 38.1166, 'lon': 13.3636}}, {'city': 'Pavia', 'country': 'Italy', 'facility': '1182.71.3907 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'city': 'Pescara', 'country': 'Italy', 'facility': '1182.71.3919 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 42.4584, 'lon': 14.20283}}, {'city': 'Amadora', 'country': 'Portugal', 'facility': '1182.71.3502 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 38.75382, 'lon': -9.23083}}, {'city': 'Lisbon', 'country': 'Portugal', 'facility': '1182.71.3504 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'city': 'Porto', 'country': 'Portugal', 'facility': '1182.71.3503 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 41.1485, 'lon': -8.61097}}, {'city': 'Ponce', 'country': 'Puerto Rico', 'facility': '1182.71.1129 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 18.01031, 'lon': -66.62398}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': '1182.71.3401 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': '1182.71.3402 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': "L'Hospitalet de Llobregat", 'country': 'Spain', 'facility': '1182.71.3403 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'city': 'Madrid', 'country': 'Spain', 'facility': '1182.71.3405 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': '1182.71.3407 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': '1182.71.3408 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'city': 'Bangkok', 'country': 'Thailand', 'facility': '1182.71.6604 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'city': 'Bangkok Noi', 'country': 'Thailand', 'facility': '1182.71.6601 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 13.76266, 'lon': 100.47798}}, {'city': 'Chiang Mai', 'country': 'Thailand', 'facility': '1182.71.6605 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 18.79038, 'lon': 98.98468}}, {'city': 'Khon Kaen', 'country': 'Thailand', 'facility': '1182.71.6602 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 16.44671, 'lon': 102.833}}, {'city': 'Nonthaburi', 'country': 'Thailand', 'facility': '1182.71.6606 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 13.86075, 'lon': 100.51477}}, {'city': 'Phathumwan', 'country': 'Thailand', 'facility': '1182.71.6603 Boehringer Ingelheim Investigational Site'}, {'city': 'Nassau', 'country': 'The Bahamas', 'facility': '1182.71.1016 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 25.05823, 'lon': -77.34306}}], 'overallOfficials': [{'name': 'Boehringer Ingelheim', 'role': 'STUDY_CHAIR', 'affiliation': 'Boehringer Ingelheim'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boehringer Ingelheim', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Boehringer Ingelheim, Study Chair', 'oldOrganization': 'Boehringer Ingelheim'}}}}